D
80.51
-3.62 (-4.30%)
| 前收盘价格 | 84.13 |
| 收盘价格 | 84.03 |
| 成交量 | 835,881 |
| 平均成交量 (3个月) | 915,360 |
| 市值 | 4,401,178,624 |
| 价格/销量 (P/S) | 2.62 |
| 股市价格/股市净资产 (P/B) | 3.83 |
| 52周波幅 |
| 营业利益率 (TTM) | -2,852.71% |
| 稀释每股收益 (EPS TTM) | -2.83 |
| 季度收入增长率 (YOY) | 33.10% |
| 总债务/股东权益 (D/E MRQ) | 0.43% |
| 流动比率 (MRQ) | 15.98 |
| 营业现金流 (OCF TTM) | -90.87 M |
| 杠杆自由现金流 (LFCF TTM) | -52.44 M |
| 资产报酬率 (ROA TTM) | -20.04% |
| 股东权益报酬率 (ROE TTM) | -28.73% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Dianthus Therapeutics, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
0.0
| 分析师共识 | 4.0 |
| 内部交易活动 | -1.5 |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.00 |
|
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 7.87% |
| 机构持股比例 | 119.90% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Fairmount Funds Management Llc | 31 Mar 2026 | 2,537,191 |
| Avidity Partners Management Lp | 31 Mar 2026 | 2,104,184 |
| Fred Alger Management, Llc | 31 Mar 2026 | 1,161,923 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 145.00 (Oppenheimer, 80.10%) | 购买 |
| 中 | 130.00 (61.47%) | |
| 低 | 103.00 (Wedbush, 27.93%) | 购买 |
| 平均值 | 124.71 (54.90%) | |
| 总计 | 7 购买 | |
| 平均价格@调整类型 | 82.68 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Wedbush | 12 Mar 2026 | 103.00 (27.93%) | 购买 | 80.32 |
| 10 Mar 2026 | 80.00 (-0.63%) | 购买 | 86.92 | |
| Baird | 10 Mar 2026 | 132.00 (63.95%) | 购买 | 86.92 |
| Clear Street | 10 Mar 2026 | 130.00 (61.47%) | 购买 | 86.92 |
| Raymond James | 10 Mar 2026 | 123.00 (52.78%) | 购买 | 86.92 |
| HC Wainwright & Co. | 09 Mar 2026 | 130.00 (61.47%) | 购买 | 79.23 |
| Oppenheimer | 09 Mar 2026 | 145.00 (80.10%) | 购买 | 79.23 |
| Truist Securities | 09 Mar 2026 | 110.00 (36.63%) | 购买 | 79.23 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| RANDHAWA SIMRAT | - | 89.45 | -26,530 | -2,373,109 |
| 累积净数量 | -26,530 | |||
| 累积净值 ($) | -2,373,109 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 89.45 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| RANDHAWA SIMRAT | 职员 | 01 Jun 2026 | 自动卖出 (-) | 26,530 | 89.45 | 2,373,109 |
| RANDHAWA SIMRAT | 职员 | 01 Jun 2026 | 执行期权 | 26,530 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合